← Back to patent-cliff list
Lysergic acid diethylamide (Mind Medicine/The University Hospital of Basel)
Tier C — Watch / tradeLysergic acid diethylamide (Mind Medicine/The University Hospital of Basel)
The University Hospital of Basel
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：5-HT2A
Indications (approved)：Major depressive disorder, Anxiety disorder, Attention deficit hyperactivity disorder
Regional status
US
Phase III
2024-12-11
EU
Phase III
2025-01-29
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lysergic acid diethylamide (Mind Medicine/The University Hospital of Basel)?
Approved indications include: Major depressive disorder, Anxiety disorder, Attention deficit hyperactivity disorder.
When does the Lysergic acid diethylamide (Mind Medicine/The University Hospital of Basel) patent expire?
No public expiry year is available for Lysergic acid diethylamide (Mind Medicine/The University Hospital of Basel) yet; this page updates once verified.
How do I get a quote for Lysergic acid diethylamide (Mind Medicine/The University Hospital of Basel) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22